Cargando…
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
PURPOSE: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate that induces osteoclast apoptosis and inhibits bone resorption by inhibiting the mevalonate pathway. Its benefit for the prevention of skeletal complications due to bone metastases has been established. However, the antitumor eff...
Autores principales: | Hasegawa, Yoshie, Tanino, Hirokazu, Horiguchi, Jun, Miura, Daishu, Ishikawa, Takashi, Hayashi, Mitsuhiro, Takao, Shintaro, Kim, Seung Jin, Yamagami, Kazuhiko, Miyashita, Masaru, Konishi, Muneharu, Shigeoka, Yasushi, Suzuki, Masato, Taguchi, Tetsuya, Kubota, Tomoyuki, Akazawa, Kouhei, Kohno, Norio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669153/ https://www.ncbi.nlm.nih.gov/pubmed/26633806 http://dx.doi.org/10.1371/journal.pone.0143643 |
Ejemplares similares
-
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials
por: Kroep, J.R., et al.
Publicado: (2015) -
Chyle leakage after axillary node sampling in a patient with breast cancer: a case report
por: Kohno, Norio, et al.
Publicado: (2020) -
The Safety of Chemotherapy for Breast Cancer Patients with Hepatitis C Virus Infection
por: Miura, Yuji, et al.
Publicado: (2013) -
P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases
por: Yoshimori, Mayumi, et al.
Publicado: (2015) -
Can Zoledronic Acid be Beneficial for Promoting Tumor Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
por: Charehbili, Ayoub, et al.
Publicado: (2013)